医学
前列腺切除术
免疫疗法
肿瘤科
免疫系统
内科学
前列腺癌
新辅助治疗
泌尿科
前列腺
前列腺特异性抗原
CD8型
化疗
原发性肿瘤
生化复发
手术切缘
转移
根治性手术
激素疗法
局限性疾病
放射治疗
临床研究阶段
抗原
作者
Braden Millan,Alexander P. Kenigsberg,Charles Hesswani,Christopher R. Koller,Sahil H. Parikh,Zoë Blake,Hangcheng Fu,Ruben Blachman-Braun,Patrick Michael,Sandeep Gurram,Barış Türkbey,Howard L. Parnes,Fatima H. Karzai,Renee Nicole Donahue,Jeffrey Schlom,James L. Gulley,Peter A. Pinto
出处
期刊:The Prostate
[Wiley]
日期:2026-08-31
卷期号:86 (15): 1518-1524
摘要
BACKGROUND: Biochemical recurrence (BCR) following radical prostatectomy (RP) occurs in 20%-40% of patients with localized prostate cancer. Neoadjuvant PROSTVAC has been shown to enhance T-cell infiltration into the tumor immune microenvironment, but whether these immunologic changes translate into improved long-term oncologic outcomes remains unknown. PATIENTS AND METHODS: This secondary analysis evaluated 26 patients from a Phase II neoadjuvant PROSTVAC trial who underwent RP. Patients received recombinant vaccinia-PSA-TRICOM priming followed by three fowlpox-PSA-TRICOM boosts before surgery. Tumor immune responses (CD4 + /CD8 + T-cell infiltration) and peripheral antigen-specific T-cell responses to PSA, MUC-1, and brachyury were previously assessed. Primary outcomes included BCR-free survival (BCR-FS) and metastatic progression at extended follow-up. RESULTS: From May 2014 to June 2017, 26 patients were enrolled, received neoadjuvant PROSTVAC, and subsequently underwent RP. Eighteen (69.2%) patients had NCCN® unfavorable-intermediate, high, or very high-risk disease at baseline. At a median follow-up of 8.9 years (range 7.0-10.1), BCR occurred in six patients (23.1%), and none developed metastatic disease. Comparing pre- and post-PROSTVAC peripheral antigen-specific T-cell responses, patients with PSA-specific immune responses had 100% 8-year BCR-FS, compared with 70.0% in nonresponders (p = 0.247). Those with any tumor-associated antigen response demonstrated 85.7% versus 66.7% 8-year BCR-FS (p = 0.149). Patients with CD4+ or CD8 + T-cell responses at the tumor site or invasive margin had 86.2% versus 58.9% 8-year BCR-FS (p = 0.257). CONCLUSION: Neoadjuvant PROSTVAC may have oncologic activity in localized prostate cancer, as we observed a longer BCR-FS in immune responders and no metastatic progression in a small cohort. Further investigation of the biological mechanism by which therapeutic immunotherapy may establish durable antitumor immunity in localized prostate cancer is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI